DexCom, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DXCM research report →
Range $86 – $115
Price Chart
About the company
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners.
- CEO
- Jacob Steven Leach
- IPO
- 2005
- Employees
- 11,050
- HQ
- San Diego, CA, US
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive recovery regime after a deep 52-week range, trading above its 200-day average but still below the 52-week high. That keeps the longer-term trend positive, though the setup still needs sustained follow-through to reclaim the prior peak.
Street sentiment is firmly positive: the consensus is Buy with a 97.85 target, well above the last close. Recent action has leaned bullish, with multiple target raises and Barclays initiating at Overweight, while the broader rating mix remains heavily tilted to Buy.
DexCom has a solid beat pattern, with 6 of the last 8 quarters topping EPS estimates and the last four all beating. Next-year EPS is modeled at 3.13 versus 2.54 TTM, so shareholders should watch whether revenue growth and margin discipline keep that upgrade path intact.
Recent insider activity skews to net selling, but much of the tape includes automatic or non-discretionary items tied to awards, in-kind transfers, and a gift. The clearest signal is repeated open-market selling by several executives and one director, which tempers the otherwise constructive operating backdrop.
Profitability remains strong, with a 63.4% gross margin, 23.98% operating margin, and 19.42% net margin. Growth is still healthy at 11.2% revenue growth and 2.6% earnings growth, while free cash flow reached $1.80 billion and the balance sheet carries $609 million of net cash.
DexCom stands out on margin quality and cash generation versus many med-tech peers, supported by a premium CGM franchise. The valuation is not cheap at 31.45x earnings, so the setup favors continued execution rather than multiple expansion alone.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $29.58B
- P/E
- 31.86
- Fwd P/E
- 29.35
- PEG
- 0.80
- P/S
- 6.03
- P/B
- 12.20
- EV/EBITDA
- 20.12
- Div Yield
- 0.00%
- Gross Margin
- 63.42%
- Op Margin
- 23.98%
- Net Margin
- 19.41%
- ROE
- 36.50%
- ROIC
- 23.98%
Latest fiscal year · YoY change
- Revenue
- $4.66B+15.6%
- Gross Profit
- $2.80B+14.9%
- Op Income
- $911.80M
- Net Income
- $836.30M+45.1%
- EPS
- $2.14+46.6%
- OCF Growth
- +45.6%
- FCF Growth
- +70.8%
- 52W High
- $92.59
- 52W Low
- $56.72
- 50D MA
- $84.01
- 200D MA
- $75.27
- Beta
- 1.44
- RSI (14)
- 43
- Avg Volume
- 4.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Dexcom delivered 11% third-quarter revenue growth, expanded margins, and raised full-year margin guidance while pointing to stronger access, product rollout, and cash returns ahead.· October 29, 2026
- Q3 revenue was $1.34 billion, up 11% year over year on both reported and organic basis; U.S. revenue grew 14% to $970 million and international revenue grew 5% to $375 million.
- Gross profit was $875.3 million, or 65.1% of revenue, up about 380 basis points from 61.3% a year ago; operating margin rose to 25.3% and adjusted EBITDA margin to 32.4%.
- Management said it still expects a CMS decision on non-insulin type 2 coverage this year, with implementation currently expected in mid-2027, and highlighted CONNECT publication in NEJM as a key evidence catalyst.
- Dexcom reiterated strong uptake of G7 15 Day, said it is on track to convert nearly 50% of its U.S. customer base by year-end, and noted a 4- to 5-point improvement in survivability after the adhesive update.
- The company ended the quarter with about $1.8 billion in cash, generated over $900 million of free cash flow in the first three quarters, authorized another $1 billion buyback, and announced a new international distribution deal that will take a European partner direct next year.
Third-quarter 2026 worldwide revenue was $1.34 billion, compared with $1.21 billion in Q3 2025, up 11% reported and 11% organic. U.S. revenue was $970 million versus $852 million a year ago, up 14%; international revenue was $375 million, up 5% reported and organic. Gross profit was $875.3 million, or 65.1% of revenue, versus 61.3% last year. Operating income was $339.5 million, or 25.3% of revenue, versus $272.9 million, or 22.6%, last year; adjusted EBITDA was $435.2 million, or 32.4% of revenue, versus $368.4 million, or 30.5%. Net income was $275 million, or $0.73 per share. For full-year 2026, Dexcom updated revenue guidance to $5.20 billion to $5.25 billion, representing 12% to 13% growth. At the midpoint, management said this includes pass-through of Q3 outperformance and about $5 million of incremental foreign-exchange headwinds, implying 10% Q4 growth at the midpoint. Full-year non-GAAP gross margin guidance stays at approximately 64%, while non-GAAP operating profit margin guidance rises to approximately 24% and adjusted EBITDA margin guidance to approximately 32%.
Jake Leach framed the quarter as evidence that Dexcom is executing across four priorities: category growth, stronger clinical evidence, a more personalized product portfolio, and better operations. He emphasized share gains in the U.S., especially in type 2 diabetes including non-insulin users, and said CONNECT gives Dexcom a stronger case for broader reimbursement and eventual standards-of-care changes. His tone was confident and expansive, repeatedly pointing to the company’s long-term plan, upcoming access expansion, and product roadmap including Stelo, G7 15 Day, and the next-generation G8 platform.
Jereme Sylvain focused on the financial momentum: 11% revenue growth, gross margin of 65.1%, operating margin of 25.3%, and adjusted EBITDA margin of 32.4%. He said gross margin improved roughly 380 basis points year over year due to manufacturing efficiencies, freight and quality improvements, and the G7 15 Day ramp, though Ireland startup costs will create some near-term pressure as the facility ramps. He also highlighted over $900 million of free cash flow through the first three quarters, about $1.8 billion of cash and cash equivalents, completion of the $1 billion 2026 repurchase goal, and a new $1 billion buyback authorization; on capital allocation, he said the company continues to favor tuck-in M&A and announced a new Europe distributor acquisition deal that will be taken direct next year.
Analysts pressed management on category growth, pricing pressure, a CVS-related PBM contract loss, and whether these issues could threaten 2027 growth. Management said it has not seen a broad pricing degradation, described the CVS matter as less than 4% of U.S. revenue, and argued that patients often still have alternate access paths through medical benefit or DME; it also said the company plans to launch Dexcom Direct early next year to help patients navigate coverage. Questions on CONNECT and CMS timing drew a consistent answer: management still expects a Medicare coverage decision this year and mid-2027 implementation, and it believes CONNECT will influence ADA standards of care and broader payer adoption.
The bull case from this call is that Dexcom is still growing in a stable CGM market while taking share, especially in the U.S. and in non-insulin type 2. Management believes CONNECT, NEJM publication, and upcoming standards-of-care updates could accelerate reimbursement and expand the addressable market, while G7 15 Day, Stelo, Dexcom Direct, and international direct-market expansion provide additional growth levers.
The main risks discussed were reimbursement and channel disruption, especially the PBM/formulary changes and broader payer negotiations. Management also flagged that international growth is lapping prior reimbursement wins, Ireland ramp-up will temporarily pressure margins, and next-year growth expectations still depend on conversion of evidence into coverage and on successful execution of new launches and access expansion.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 372.95M
- Float Shares
- 371.59M
of shares held by institutions
1,031 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for DXCM, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | May 1, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 13, 26 | Filing → |
| John BoozmanSenate · AR | Buy | Jan 26, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 29, 26 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Sep 22, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 29, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Jun 2, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 16, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | May 12, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Buy | May 8, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | May 15, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Apr 8, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | Apr 7, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Apr 8, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 49.07M | ▼ 381.67K |
| Blackrock, Inc. | 38.50M | ▲ 254.05K |
| Vanguard Capital Management LLC | 24.70M | ▼ 505.27K |
| Vanguard Portfolio Management LLC | 19.79M | ▲ 134.62K |
| State Street Corp | 18.90M | ▲ 516.18K |
| Invesco Ltd. | 15.97M | ▲ 680.78K |
| Baillie Gifford & Co | 14.52M | ▼ 279.97K |
| Geode Capital Management, LLC | 12.46M | ▲ 32.64K |
| Alliancebernstein L.P. | 11.69M | ▼ 1.23M |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 11.26M | ▲ 1.52M |
| Wellington Management Group Llp | 8.53M | ▼ 798.77K |
| Arrowstreet Capital, Limited Partnership | 7.83M | ▲ 952.08K |
Held by 2,063 ETFs
Biggest fund positions in DXCM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Brown Michael Jon | sell | 1,700 |
| Nov 8, 26 | Brown Michael Jon | other | 1,451 |
| Nov 8, 26 | Leach Jacob Steven | other | 1,451 |
| Nov 8, 26 | Stern Sadie | other | 1,451 |
| Nov 8, 26 | Sylvain Jereme M | other | 1,451 |
| Oct 30, 26 | Ashley Euan A. | other | 2,389 |
| Oct 27, 26 | Stern Sadie | sell | 2,565 |
| Oct 15, 26 | Brown Michael Jon | sell | 1,700 |
| Sep 28, 26 | Stern Sadie | sell | 2,565 |
| Sep 14, 26 | AUGUSTINOS NICHOLAS | sell | 1,550 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DXCM coverage
Recent articles, reports, and earnings notes.

DexCom (DXCM): Growth Broadens, but Valuation Limits Upside
DexCom posted 13% Q2 revenue growth, 46% EPS growth, and raised 2026 guidance, but the stock still screens as a Hold at a rich valuation. The report highlights expanding reimbursement, strong G7 15 Day adoption, and a growing opportunity in non-insulin type 2 diabetes.

DexCom, Inc. (DXCM) drops 6.4% on high volume
DexCom, Inc. (DXCM) drops sharply on heavy trading as investors reposition ahead of earnings and reassess valuation. The move comes despite recent positive clinical news from the CONNECT trial, suggesting the selloff is more about near-term risk and profit-taking than a change in the company’s long-term growth story.

MiniMed Group IPO: The Bull and Bear Case for a Diabetes Carve-Out
MiniMed Group, Inc. Common Stock When Issued is expected to list on NASDAQ on 2026-10-01 under the symbol MMEDV. The price range has not been disclosed yet. The bull case is a global diabetes-tech platform with $3.102 billion in fiscal 2026 sales; the bear case is execution risk, heavy competition, and a float dominated by Medtronic.
Want a deeper read on DXCM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone
businesswire.com · Nov 19
DexCom Sees Record New Patients in 2026 as Medicare Coverage Decision Looms
marketbeat.com · Nov 18
DexCom, Inc. (DXCM) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
DexCom, Inc. $DXCM Shares Sold by Aberdeen Group plc
defenseworld.net · Nov 17
Commonwealth Equity Services LLC Purchases 10,738 Shares of DexCom, Inc. $DXCM
defenseworld.net · Nov 16
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
zacks.com · Nov 13
Dexcom Announces Upcoming Conference Presentation
businesswire.com · Nov 10
DexCom to Launch 15-Day G7 CGM System in Canada This November
zacks.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice